By Bruce Gil – Quartz –
Google’s anti-aging company Calico released disappointing trial results of its first ever drug.
Calico’s fosigotifator was tested for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease that affects nerve cells in the brain and spinal cord and leads to paralysis. It was part of the HEALEY ALS Platform Trial, which is testing a series of drugs against the condition.
Calico said on Monday that fosigotifator did not meet its primary or secondary goals after a 24-week trial.
